USPTO Patent Grant: Plasma piRNA Combination for Gastric Cancer Diagnosis

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 17th, 2026

Detected March 22nd, 2026

Summary

The USPTO has granted patent US12580080B2 to The First Affiliated Hospital of Wenzou Medical University for a plasma piRNA combination for the early diagnosis of gastric cancer. The patent describes a diagnostic model that uses piRNA expression profiles to predict gastric cancer risk with high accuracy.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12580080B2 to The First Affiliated Hospital of Wenzou Medical University. This patent covers a plasma piRNA combination and its application for the early diagnosis of gastric cancer. The invention utilizes a piRNA expression profile specific to the Chinese population to develop an early diagnostic model, aiming to improve accuracy and reduce detection costs. The model employs a Lasso Logistic regression approach to simplify variable inclusion, facilitating broader application and popularization.

This patent grant represents a new development in diagnostic technology for gastric cancer. While it does not impose direct compliance obligations on regulated entities, it signifies innovation in the field of medical diagnostics and biotechnology. Companies involved in developing diagnostic tools, particularly those focusing on oncology or RNA-based diagnostics, should be aware of this patented technology. The USPTO filing date was September 30, 2024, and the patent is set to be granted on March 17, 2026.

Source document (simplified)

← USPTO Patent Grants

Plasma piRNA combination for early diagnosis of gastric cancer and application thereof

Grant US12580080B2 Kind: B2 Mar 17, 2026

Assignee

THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY

Inventors

Xian Shen, Jianjian Zheng, Xiaodong Chen, Lifan Lin, Feng Jiang, Xinmiao Li, Qiqi Tao, Weizhi Zhang

Abstract

A plasma piwi-interacting RNA (piRNA) combination for early diagnosis of gastric cancer and application thereof are provided. Based on the plasma piRNA expression profile of the Chinese population, the present invention obtains a plasma piRNA combination for early diagnosis of gastric cancer, and establishes an early diagnosis model for gastric cancer based on the plasma piRNA combination. The model can predict the incidence risk of gastric cancer with relatively high accuracy, which helps to reduce the cost of detection. At the same time, the present invention uses a Lasso Logistic regression model, which greatly reduces the number of variables included in the model and facilitates the application and popularization of the model.